Tag - eisai

 
Menu
Search
 
November 22, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

EISAI

Japan Times
BUSINESS
Nov 30, 2022
Eisai Alzheimer’s drug sparks debate over benefits as risks like brain bleeding emerge
The key issue is whether the modest slowing of the disease is meaningful to individual patients and their families, especially in light of the potential side effects.
Japan Times
BUSINESS / Markets
Nov 29, 2022
Eisai and Biogen plunge after report of second death in Alzheimer’s trial
The case involved a 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, a report said.
Japan Times
COMMENTARY / World
Oct 4, 2022
New Alzheimer's drug from Biogen and Eisai is just the beginning
A successful late-stage trial of lecanemab gives researchers promising new avenues for tackling this hard-to-beat disease.
Japan Times
WORLD / Science & Health / ANALYSIS
Sep 30, 2022
Eisai drug's trial success raises hope for Alzheimer's prevention
Scientists have already begun to debate whether the benefit of the drug is robust enough, but to many researchers, the findings suggest that preventing decline altogether is possible.
Japan Times
JAPAN / Science & Health
Sep 28, 2022
Alzheimer’s progression slowed by drug in major trial
The drug slowed cognitive decline in people with early Alzheimer's by 27% over 18 months when compared with a placebo using a common rating scale.
Japan Times
BUSINESS / Companies
Jul 6, 2022
Eisai says Alzheimer’s drug will get priority review in U.S.
Under the accelerated approval pathway, drugs can be approved based on their ability to remove amyloid, a hallmark of the disease, from the brain.
Japan Times
BUSINESS
Apr 9, 2022
Japan's Eisai still seeking accelerated U.S. review of Alzheimer's drug
The firm said it plans to seek a quick approval even after the Medicare health plan decided to limit coverage of medicines approved in that manner.
Japan Times
WORLD / Science & Health
Jan 12, 2022
Biogen stung as U.S. limits coverage of Alzheimer’s therapy
Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.
Japan Times
BUSINESS / Companies
Jul 13, 2021
Eisai pushes second Alzheimer's drug despite call to probe U.S. approval of first
The U.S. Food and Drug Administration's June approval of Aduhelm caused resignations among a panel of independent experts who said the therapy was ineffective.
Japan Times
WORLD / Science & Health / ANALYSIS
Jun 11, 2021
U.S. FDA faces mounting criticism over Alzheimer's drug approval
The drug was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the disease.
Japan Times
JAPAN / Science & Health
Jun 8, 2021
Changing the game for Alzheimer's treatment, U.S. approves Eisai and Biogen's drug
The approval appears to signal a fundamental shift in the way the FDA thinks about Alzheimer's disease, which could have lasting ramifications for other drugs in the pipeline.
Japan Times
BUSINESS / Companies
Feb 2, 2020
Japanese firms take Brexit in stride but worry over British prospects for trade talks with EU
Japanese companies in Britain are taking the British exit from the European Union in stride, but some are wary that if Britain-EU trade talks falter, prospects for business in Europe will become uncertain.
Japan Times
BUSINESS
Dec 6, 2019
Biogen builds case for its Alzheimer's drug, but skeptics say more data needed
Biogen Inc. laid out more data Thursday on its experimental Alzheimer's drug, raising no major safety alarms but also offering little compelling evidence that the drug, once declared a failure, actually works.
Japan Times
BUSINESS
Oct 27, 2019
Prolonged Brexit uncertainty frustrating Japanese companies
Japanese manufacturers are growing frustrated yet again over another delay in Britain's withdrawal from the European Union, as the prolonged confusion is raising concerns over disruptions to their businesses and supply chains.
Japan Times
BUSINESS
Oct 23, 2019
Biogen and Eisai revive plans for Alzheimer's drug aducanumab, but prospects still shaky
Biogen Inc. revived plans on Tuesday to seek U.S. approval for the Alzheimer's treatment aducanumab and said data from more patients in two discontinued studies showed the drug reduced the decline of patients.
Japan Times
JAPAN
Jul 12, 2017
Pill-popping is a business worth watching for Japan's drugmakers
To eke out growth in one of the developed world's most sluggish pharmaceutical markets, Japanese drugmakers are turning to the pill-popping behavior of their customers.
WORLD / Science & Health
Mar 25, 2015
Alzheimer's debate revived as Biogen's drug trial advances
Just days after Biogen Inc. revealed promising early data from an experimental Alzheimer's treatment, new research from the Mayo Clinic may revive a long-running debate over whether the drug industry is focusing on the right target in developing therapies to treat the disease.
Two of America’s biggest debt holders are dumping Treasurys
The U.S. Treasury building in Washington. Investors in Japan and China sold a pile of U.S. debt in the last quarter, just before the U.S. presidential election.
Ishiba aggravates his own political failures with diplomatic faux pas
Prime Minster Shigeru Ishiba is greeted at the APEC summit in Lima by Canadian Prime Minister Justin Trudeau on Friday. The Japanese leader was criticized for remaining seated while meeting several world leaders at the event.
Japan's 3.31 million visitors in October set monthly record
Kiyomizu Temple in Kyoto in December 2023. Famous autumn leaf colors contributed to increased tourism demand last month from many markets across Asia, Europe and North America, the Japan National Tourism Organization has said.
Japan ranks last in romance satisfaction for second straight year
In a survey of 31 countries, Japan ranked last in terms of those who felt loved, with just 51% of respondents saying so.
Ruling coalition and DPP strike last-minute deal over economic policy
DPP policy chief Makoto Mahaguchi speaks at the party's policy gathering in Tokyo on Wednesday.
Japan, U.K. and Italy discuss inviting more countries to joint fighter project
A new concept model of a next-generation fighter jet to be jointly developed by Japan, Britain and Italy is on display in Farnborough, Hampshire, in July.
Haruki Murakami's 'The City and Its Uncertain Walls' gives deep deja vu
For “The City and Its Uncertain Walls,” translated into English by Philip Gabriel, Haruki Murakami confronts the ghosts who won't leave him alone.
Japanese expats in Asia find community through rugby
The Taiwan Fivewoods celebrate their victory at the 2023 Asian Japanese Rugby Cup in December of last year.
In Fukushima, a weekend of prose, poetry and translation
Aomori-based writer JJ Carter presented on tabletop gaming as creative inspiration for building characters and narratives.
For Dr. Nakamats, aging is just experience in action
Though he didn't win the recent gubernatorial election in Tokyo, the 96-year-old Dr. Nakamats' run was seen as inspirational in Japan's aging society.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo’s Shinjuku Ward.
Kabukicho: Tokyo’s ‘stadium of desire’

Longform

Construction takes place on the Takanawa Gateway Convention Center in Tokyo, slated to open in 2025.
A boom for business tourism in Japan?
By Kathryn Wortley

SUSTAINABLE JAPAN

mission sustainability vol.12 : Kose Corp.Kose takes pride in creating beauty in the world
mission sustainability vol.12 : Kose Corp.Kose takes pride in creating beauty in the world

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER